Drugs / UB-851
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT02708914 | Mar 2016 → Oct 2021 | anemia | UBI Pharma Inc. | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | UB-851 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02708914 ↗ |
| Modality | Protein / enzyme biologic | “UB-851 (rhEPO) has been developed as a biosimilar product to Eprex®.” NCT02708914 ↗ |
| Route | Intravenous | “Intravenous UB-851 and Eprex®” NCT02708914 ↗ |